Trial Profile
Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2023
Price :
$35
*
At a glance
- Drugs Valaciclovir (Primary)
- Indications Herpes genitalis; Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 12 Jun 2007 Status changed from in progress to completed.
- 14 Dec 2005 New trial record.